# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹8,805 Cr** ($992 Mn) (+8% YoY, +3% QoQ) * **EBITDA:** **₹2,351 Cr** ($265 Mn) (+3% YoY/QoQ) · **Margin: 7%** (-174 bps YoY) * **PAT:** **₹1,437 Cr** ($162 Mn) (+14% YoY, flat QoQ) · **Margin: 16%** * Diluted EPS: ₹17.25 * **ROCE:** **22%** * **Free Cash Flow:** **₹1,046 Cr** ($118 Mn) · **Net Cash Surplus: ₹2,751 Cr** ($310 Mn) ## B. Revenue Growth * **Steady Top-Line Momentum:** Near double-digit growth driven by broad-based expansion and integration of acquired consumer healthcare, despite headwinds from **Lenalidomide** and US price erosion. * **US Pricing Stabilization:** Base product pricing in the US generics market has stabilized, with future erosion expected to be limited to new launches and **insignificant in magnitude**. ## C. Gross Margin * **Margin Pressure from Mix & Inventory:** Gross margin declined significantly YoY due to lower **Lenalidomide** sales, price erosion, and one-time inventory provisions, with PSAI margin at **18%** versus **1%** in Global Generics. * **PSAI Margin Recovery Path:** PSAI gross margin is on an improving trajectory, with management guiding for **20–25%** over the next 1–2 years on better product mix and operating leverage. * **Cost Discipline Underway:** Cost reduction initiatives targeting **500–600 bps** are partially realized, with full benefits expected in upcoming quarters. ## D. EBITDA & Profitability * **Underlying EBITDA Resilience:** Despite reported margin compression, underlying EBITDA margin was **5%** after adjusting for one-time VAT and pipeline charges, reflecting core stability. * **Exceptional Items Impact PBT:** PBT margin of **8%** included a one-time VAT provision; adjusted margin was **6%**, with strong operating leverage in non-impacted segments. * **Low Tax Rate Boosts Net Income:** Effective tax rate of **2%** (vs. 30% prior year) due to favorable jurisdictional mix, significantly enhancing PAT growth despite modest pre-tax expansion. * **Margin Guidance Reinforced:** Management reaffirmed commitment to **28–30% operating margin** by FY27, with SG&A and R&D held at **28%** and **7%** respectively, signaling strong **margin discipline**. ## E. Cash Flow & Capex * **Robust Cash Generation:** Strong free cash flow of **₹1,046 Cr** funded strategic capex and acquisitions, resulting in a **net cash surplus of $310 million**. * **Active FX Hedging:** Significant foreign exchange risk mitigation via **$502 Mn** hedged at **₹9/$** through Dec-2026 and **RUB 28 Bn** hedged at **₹0.3/RUB** for near-term maturities. --- # 2. Segment & Geography Mix ## A. Key Figures * **North America Generics Revenue:** **$373 Mn** (–16% YoY, –7% QoQ) * **Europe Generics Revenue:** **€135 Mn** (+115% YoY, +3% QoQ) * **India Business Revenue:** **₹1,578 Cr** (+13% YoY, +7% QoQ) * **Emerging Markets Revenue:** **₹1,655 Cr** (+14% YoY, +18% QoQ) * **PSAI Revenue:** **$108 Mn** (+8% YoY, +13% QoQ) ## B. North America Generics * **Sharp Revenue Decline:** Performance weakened by significant price erosion in key products like Lenalidomide, despite launching seven new products. * **Limited Revlimid Contribution:** U.S. business to see reduced Revlimid impact in Q3, with minimal or no contribution expected beyond, signaling near-term headwinds. * **Portfolio Reset Underway:** Strategic shift toward first-to-market opportunities as legacy products (e.g., Conjugated Estrogen, Nuvaring) are phased out. ## C. Europe Generics * **Exceptional Growth Momentum:** Revenue surged on the back of the acquired NRT portfolio and strong new product execution, with underlying growth remaining robust at 6%. * **Biosimilars Driving Expansion:** Successful launches of Rituximab, Denosumab, and Bevacizumab in the UK and other European markets are accelerating biologics adoption. * **Cross-Regional Leverage:** Growth amplified by synergies from the U.S. pipeline and targeted biosimilar rollouts, reinforcing Europe as a key growth engine. ## D. India Business * **Outperformance in Domestic Market:** Revenue growth outpaced the broader IPM, with market share advancement to 9th position (IQVIA MAT), driven by volume, pricing, and new launches. * **Strategic Inorganic Growth:** Integration of Stugeron® and 11 new brand launches strengthened portfolio, reflecting a hybrid strategy of acquisitions and innovation. * **Pricing Resilience:** Price growth held steady at **5%**, in line with historical trends, with remainder of growth from volumes and new products. ## E. Emerging Markets * **Strong Double-Digit Growth:** Revenue expansion fueled by 24 new product launches, favorable forex, and momentum in injectables, oncology, and biologics. * **Stugeron® Adds Scale:** Acquired brand contributes **over ₹100 Cr** in combined India and EM revenue, though current quarter impact is negligible. * **Management Transition Enhancing Margins:** Ongoing shift from Haleon-managed markets to internal control (with two waves remaining) is exceeding growth and margin expectations, reducing fee outflows. * **Confidence in Sustained Growth:** Leadership expresses strong conviction in maintaining double-digit ex-US growth over the next 1–2 years via localized strategies. --- # 3. Product & Therapy Performance ## A. Key Figures * **Semaglutide Volume:** **20 Mn units** expected absorption (12–15 months post-approval) · **15 Mn units** targeted for 2027 (+ potential upside) * **Peptide Capacity:** Up to **800 kg** built at PSAI (current sales very small) ## B. Key Product Sales * **Base Business Pressure:** Lenalidomide and **five other products** face competitive intensity and price erosion, though overall impact remains contained. * **Emerging Growth Vector:** Peptide platform at PSAI is underutilized but positioned for future scale with **800 kg capacity** in place. ## C. Biosimilar Progress * **Global Semaglutide Rollout:** Full **20 Mn unit volume** expected to be absorbed across **87 countries**, led by India, Brazil, Turkey, and partner-driven distribution in Latin America and Asia. * **Confidence in Demand:** B2B partnerships for API and delivery devices support market sequencing by **COPP/non-COPP classifications**, with strong early traction reinforcing volume outlook. * **2027 Capacity Inflection:** Volume potential to rise to **at least 15 Mn units** in 2027, driven by product evolution and **FTO-11 qualification** enabling significant H2 capacity expansion. * **Targeted & Tiered Launch Strategy:** Denosumab and Abatacept form core of European biologics pipeline, with India and Emerging Markets included; Pembrolizumab and Nivolumab planned for India; Tocilizumab limited to domestic market. ## D. New Launches * **Portfolio Expansion via Acquisition:** Entry into anti-vertigo space through acquisition of **Stugeron® and related brands** in **18 APAC and EMEA markets** from Janssen. * **GI Portfolio Deepening in India:** Launched **Tegoprazan (PCAB®)** and **Linaclotide (Colozo®)** to strengthen domestic gastrointestinal offerings. * **Access-Focused HIV Initiative:** Partnership with **Unitaid, CHAI, and Wits RHI** to ensure affordable access to **Lenacapavir** in low- and middle-income countries. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **R&D Spend:** ₹620 Cr ($70M) (-15% YoY) · **7% of Revenue** (-203 bps YoY) ## B. Clinical Stage Assets * **Pipeline Prioritization:** R&D focus sharpened on **complex generics, GLP-1s, and biosimilars**, with rationalization of assets facing regulatory or commercial headwinds. * **Abatacept Momentum:** Phase III trial completed with positive progress; **IV version on track for BLA submission by December 2025**, supported by diversified manufacturing. * **Subcutaneous Pathway Cleared:** No Phase III required for subcutaneous Abatacept—launch contingent on IP settlement and targeted for **early 2028**. * **External Innovation Leverage:** Daratumumab licensed from **Henlius**; Denosumab co-developed with **Alvotech**; internal pipeline anchored by Abatacept. * **New Program Initiation:** Tirzepatide development underway for off-patent peptide, with **in-house and partnered manufacturing planned at FTO-11**. ## C. Regulatory Filings * **Regulatory Momentum:** Positive CHMP opinion for **denosumab**, SEC recommendation for **Semaglutide** in India, and USFDA IND acceptance for **COYA 302 (ALS)**. * **Filing Volume Strength:** **43 global generic filings** and **37 DMFs** submitted in the quarter, signaling robust pipeline execution. * **Abatacept Filing Clarity:** First submission for IV formulation by **December 2025**; approval expected in line with **patent expiry in early 2027**. * **Wegovy Requires Separate Path:** Despite shared Semaglutide trials, **weight-loss indication needs distinct regulatory application** in India. * **Rituximab as Pathfinder:** Early filing used to de-risk **Bachupally** approval process amid FFM-1 design concerns; **FFM-2 remains backup**. ## D. Manufacturing Strategy * **Dual-Sourcing for Launch Readiness:** **CMO to support Day-1 U.S. launch** of subcutaneous Abatacept, with tech transfer from **Bachupally**, ensuring supply scalability. * **Bachupally as Core Hub:** Remains central to Abatacept manufacturing and tech transfer, despite facility-specific regulatory scrutiny. * **GLP-1 Vertical Integration:** API production for Semaglutide and Liraglutide at **CTO-6**, with long-term capacity up to **800 kg**; supports **40+ peptide pipeline**. * **Fill-Finish Expansion Underway:** FTO-11 to add **two cartridge lines** (potential **5 crore units**)—**operational post-12 months**; current supply reliant on partner capacity of **2 crore pens**. * **Tirzepatide Dual Production:** Planned for **in-house and partner-led manufacturing**, mirroring strategy for other high-potential peptides. --- # 5. Manufacturing & Regulatory Risks ## A. Regulatory Inspection Outcomes * **Headline:** **FDA issued Form 483s** at both **Bachupally (5 observations)** and **Mirfield (7 observations)**, with a **CRL received for Rituximab biosimilar**, delaying U.S. approval despite European clearance. * **Headline:** Regulatory setbacks concentrated in **sterile manufacturing facilities**, though management asserts no systemic compliance issues and highlights use of **alternate fill-finish capacity (FFM-2)** as contingency. * **Headline:** **Multi-site strategy and U.S. CMO partnerships** actively mitigate U.S. regulatory and tariff risks, ensuring launch readiness via **already-approved U.S. facility** for critical biosimilars like Abatacept. ## B. Facility Compliance & Sustainability * **Headline:** **Three key facilities (CTO-5, Middleburgh, FTO-11) achieved VAI status** post-inspection, signaling improved compliance trajectory despite recent setbacks. * **Headline:** **₹54 Cr impairment** in Middleburgh tied to pipeline discontinuation, not regulatory failure; sustainability milestones include **LEED Platinum certification** and **Diamond Standard waste recognition**. ## C. Supply Chain & Market Access Strategy * **Headline:** **Dual-source manufacturing model** de-risks U.S. biosimilar launches, addressing potential **FDA, tariff, and capacity constraints** through strategic use of --- # 6. Guidance & Outlook ## A. Margin Recovery Path * **Confidence in Controllable Levers:** Management maintains strong confidence in driving margin and growth recovery through base business performance and disciplined cost management. * **Key Recovery Variables:** Pace of margin recovery hinges on **Semaglutide availability, Abatacept performance, and business development success**, with upside potential under favorable conditions. ## B. Growth Expectations * **Sustained Growth Strategy:** Growth outlook supported by new product launches, volume expansion, and **5% price increases**, with continued focus on innovation and execution. * **Lenalidomide Decline Mitigation:** Four-year preparedness for Lenalidomide decline is being executed via base business growth, cost containment, BD, and key product focus. * **Canadian Semaglutide Market Dynamics:** Market entry will be highly competitive with multiple players expected; **launch revenue remains highly uncertain**, ranging from zero to many millions. * **Regulatory-Driven Timeline:** Market formation in Canada contingent on regulatory approval, reimbursement filings, and adherence to national pricing—**no change in outlook since Q1**. ## C. Launch Timelines * **Strategic Priorities:** Focus on growing the base business, advancing **Semaglutide and Abatacept pipelines**, operational efficiency, and pursuing value-accretive M&A and partnerships. * **Margin Target Intact:** Despite high-margin Lenalidomide wind-down, commitment to achieving **25% EBITDA margin by FY27** remains unchanged.